

Health Robotics Rejects McKesson and Sets the Record Straight on Intellectual Property and Licensing Rights

Bozen, Sud-Tirol, Italy – March 28th, 2011. Health Robotics today announced its official response to McKesson’s wrongful and public allegations with regards to: 1) Health Robotics’ intellectual property and licensing rights, and 2) Health Robotics’ development partnerships with 3 Italy-based companies for CytoCare, i.v.STATION, and i.v.SOFT.

Suffering from a David/Goliath syndrome, McKesson attempted several times during the last 12 months to take sole control of the North American market for Health Robotics’ world-leading products. McKesson’s bullying actions spanned well beyond the limits permitted by the then-existing contract between the companies, and within the last 6 months, also concurrently with multiple notices of material breach of contract [including non-conformity notices issued to McKesson related to certain McKesson’s regulatory duties as the then-current organization responsible for Health Robotics’ products].

Having had no success whatsoever with its bullying strategy towards Health Robotics, unable or unwilling to cope with competition and/or to cure its breaches of contract by the end of the 90-day cure period, McKesson made up a non-existent excuse for its own failures. After Health Robotics rejected McKesson’s bullying attempts, and in a last-minute attempt to rescind its Health Robotics’ contract right before its just termination, McKesson grossly and publicly misrepresented Health Robotics’ licensing relationship with 3 Italian companies, just as McKesson’s cure period for breach of contract came perilously to an end, and thus, the contract’s termination for cause. Rather than get into a “*he said-she said*” public debate with McKesson, Health Robotics informed these 3 companies so they could fully and independently respond to McKesson’s claims.

After reviewing McKesson’s fabricated claims purporting that Health Robotics did not have the rights to exclusively license its products to McKesson, these 3 companies provided Health Robotics with official statements and affidavits that categorically dispute McKesson’s fictional claims, and leave no doubt whatsoever as to Health Robotics’ intellectual property and exclusive licensing rights for CytoCare, i.v.STATION, and i.v.SOFT. These affidavits are available for release [authorization required] to current customers and business partners with a currently valid non-disclosure agreement from: <http://www.health-robotics.com/en/about-health-robotics/ip-rights/>

Additionally, McKesson has wrongfully released to the public Health Robotics’ confidential information and trade secrets obtained under strict confidentiality covenants. Health Robotics is determined to defend its confidential information and



trade secrets in all applicable legal and commercial venues, beyond and above the company's already announced termination for cause of its contract with McKesson.

Finally, McKesson's actions and omissions have caused additional severe harm to Health Robotics, especially in relation to all the remediation tasks, distractions, and expenses that Health Robotics needed to undertake with respect to the above-mentioned regulatory non-conformities. Health Robotics is committed to remediate this and any other regulatory issues. Health Robotics has already put in place: 1) its USA-based support structure during 4Q2010 with regards to i.v.STATION and i.v.SOFT [without McKesson's participation]; 2) also during late 2010, taken the necessary steps to directly replace McKesson regulatory duties by increasing its staff to 7 FTEs dedicated to regulatory matters; and 3) expanded to CytoCare in early 2011 the USA-based support structure, post-termination for cause of the McKesson's agreement.

About Health Robotics:

Health Robotics is the undisputed global leading supplier of life-critical intravenous medication robots, providing over 175 hospital installations in 5 continents with robotics technology and software automation solutions deployed utilizing virtual high-availability technology. Its world-leading solutions CytoCare® and i.v.STATION® ONCO [hazardous IVs], i.v.STATION® [non-hazardous IVs], i.v.SOFT® [workflow engine for manual compounding], MEDarchiver® [life-critical clinical information system], and TPNstation™ [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' solutions help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff. For more information, please visit: <http://www.health-robotics.com>

For additional information, please contact:

Claudia Flaim, Marketing Coordinator

flaim@health-robotics.com

Phone: +39-0471-200-372